Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPT-300 in Major Depressive Disorder
NCT07161700Phase 2Enrolling by invitation
- Sponsor
- Seaport Therapeutics
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of GlyphAllo in major depressive disorder (MDD), sponsored by Seaport Therapeutics. Started Sep 2025; status: enrolling by invitation.
02
Drugs
GlyphAllo
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07161700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161700.